New antibody drug targets Hard-to-Treat cancers in first human trial

NCT ID NCT06636435

Recruiting now Disease control Sponsor: Chiome Bioscience Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the drug, and researchers will monitor side effects and measure how the body processes the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm hepatocellular carcinoma melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC) MALIGNANT MELANOMA PEDIATRIC CANCER SOLID TUMORS

Contacts and locations

Locations

Kanagawa Cancer Center
RECRUITING

Yokohama, Kanagawa, 241-8515, Japan
National Cancer Center Hospital
RECRUITING

Chūō, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
Niigata University Medical and Dental Hospital
RECRUITING

Niigata, Niigata, 951-8520, Japan
University of Yamanashi Hospital
RECRUITING

Chūō, Yamanashi, 409-3898, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.